These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 35575500)

  • 21. Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone.
    Jiang X; Dalebout TJ; Lukashevich IS; Bredenbeek PJ; Franco D
    J Gen Virol; 2015 Apr; 96(Pt 4):804-814. PubMed ID: 25516543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Community-based sero-prevalence of chikungunya and yellow fever in the South Omo Valley of Southern Ethiopia.
    Endale A; Michlmayr D; Abegaz WE; Asebe G; Larrick JW; Medhin G; Legesse M
    PLoS Negl Trop Dis; 2020 Sep; 14(9):e0008549. PubMed ID: 32881913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-Function of the Yellow Fever Virus Envelope Protein: Analysis of Antibody Epitopes.
    Davis EH; Barrett ADT
    Viral Immunol; 2020; 33(1):12-21. PubMed ID: 31682201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis.
    Pincus S; Mason PW; Konishi E; Fonseca BA; Shope RE; Rice CM; Paoletti E
    Virology; 1992 Mar; 187(1):290-7. PubMed ID: 1736531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Humanized monoclonal antibody 2C9-cIgG has enhanced efficacy for yellow fever prophylaxis and therapy in an immunocompetent animal model.
    Julander JG; Thibodeaux BA; Morrey JD; Roehrig JT; Blair CD
    Antiviral Res; 2014 Mar; 103():32-8. PubMed ID: 24393669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular Basis of a Protective/Neutralizing Monoclonal Antibody Targeting Envelope Proteins of both Tick-Borne Encephalitis Virus and Louping Ill Virus.
    Yang X; Qi J; Peng R; Dai L; Gould EA; Gao GF; Tien P
    J Virol; 2019 Apr; 93(8):. PubMed ID: 30760569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mapping the diverse structural landscape of the flavivirus antibody repertoire.
    Sevvana M; Kuhn RJ
    Curr Opin Virol; 2020 Dec; 45():51-64. PubMed ID: 32801077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sofosbuvir inhibits yellow fever virus in vitro and in patients with acute liver failure.
    Mendes ÉA; Pilger DRB; Santos Nastri ACS; Malta FM; Pascoalino BDS; Carneiro D'Albuquerque LA; Balan A; Freitas LHG; Durigon EL; Carrilho FJ; Rebello Pinho JR
    Ann Hepatol; 2019; 18(6):816-824. PubMed ID: 31594756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Absence of YF-neutralizing antibodies in vulnerable populations of Brazil: A warning for epidemiological surveillance and the potential risks for future outbreaks.
    Stoffella-Dutra AG; Silva de Oliveira J; Barbosa Costa G; Geessien Kroon E; Santos Abrahão J; Desiree LaBeaud A; Paiva Drumond B; Bretas de Oliveira D; de Souza Trindade G
    Vaccine; 2020 Sep; 38(42):6592-6599. PubMed ID: 32788140
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Yellow fever vaccination elicits broad functional CD4+ T cell responses that recognize structural and nonstructural proteins.
    James EA; LaFond RE; Gates TJ; Mai DT; Malhotra U; Kwok WW
    J Virol; 2013 Dec; 87(23):12794-804. PubMed ID: 24049183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure of the yellow fever NS5 protein reveals conserved drug targets shared among flaviviruses.
    Dubankova A; Boura E
    Antiviral Res; 2019 Sep; 169():104536. PubMed ID: 31202975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Yellow Fever Virus Reemergence and Spread in Southeast Brazil, 2016-2019.
    Giovanetti M; de Mendonça MCL; Fonseca V; Mares-Guia MA; Fabri A; Xavier J; de Jesus JG; Gräf T; Dos Santos Rodrigues CD; Dos Santos CC; Sampaio SA; Chalhoub FLL; de Bruycker Nogueira F; Theze J; Romano APM; Ramos DG; de Abreu AL; Oliveira WK; do Carmo Said RF; de Alburque CFC; de Oliveira T; Fernandes CA; Aguiar SF; Chieppe A; Sequeira PC; Faria NR; Cunha RV; Alcantara LCJ; de Filippis AMB
    J Virol; 2019 Dec; 94(1):. PubMed ID: 31597773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heparin removal by ecteola-cellulose pre-treatment enables the use of plasma samples for accurate measurement of anti-Yellow fever virus neutralizing antibodies.
    Campi-Azevedo AC; Peruhype-Magalhães V; Coelho-Dos-Reis JG; Costa-Pereira C; Yamamura AY; Lima SMB; Simões M; Campos FMF; de Castro Zacche Tonini A; Lemos EM; Brum RC; de Noronha TG; Freire MS; Maia MLS; Camacho LAB; Rios M; Chancey C; Romano A; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA;
    J Immunol Methods; 2017 Sep; 448():9-20. PubMed ID: 28514646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MEK/ERK activation plays a decisive role in yellow fever virus replication: implication as an antiviral therapeutic target.
    Albarnaz JD; De Oliveira LC; Torres AA; Palhares RM; Casteluber MC; Rodrigues CM; Cardozo PL; De Souza AM; Pacca CC; Ferreira PC; Kroon EG; Nogueira ML; Bonjardim CA
    Antiviral Res; 2014 Nov; 111():82-92. PubMed ID: 25241249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serological evidence of Flavivirus circulation in human populations in Northern Kenya: an assessment of disease risk 2016-2017.
    Chepkorir E; Tchouassi DP; Konongoi SL; Lutomiah J; Tigoi C; Irura Z; Eyase F; Venter M; Sang R
    Virol J; 2019 May; 16(1):65. PubMed ID: 31101058
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Flavivirus-induced antibody cross-reactivity.
    Mansfield KL; Horton DL; Johnson N; Li L; Barrett ADT; Smith DJ; Galbraith SE; Solomon T; Fooks AR
    J Gen Virol; 2011 Dec; 92(Pt 12):2821-2829. PubMed ID: 21900425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Monoclonal antibodies to flavivirus antigens induced by a vaccinal strain of yellow fever].
    Gaĭdamovich SIa; Mel'nikova EE; Mikheeva TG; Shutkova TM; Sveshnikova NA
    Vopr Virusol; 1988; 33(4):461-5. PubMed ID: 2848367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and characterization of serotype-specific monoclonal antibodies against the dengue virus-4 (DENV-4) non-structural protein (NS1).
    Gelanew T; Hunsperger E
    Virol J; 2018 Feb; 15(1):30. PubMed ID: 29409531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of monoclonal antibodies that distinguish between 17D-204 and other strains of yellow fever virus.
    Barrett AD; Mathews JH; Miller BR; Medlen AR; Ledger TN; Roehrig JT
    J Gen Virol; 1990 Jan; 71 ( Pt 1)():13-8. PubMed ID: 1689367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Yellow Fever: Integrating Current Knowledge with Technological Innovations to Identify Strategies for Controlling a Re-Emerging Virus.
    Kleinert RDV; Montoya-Diaz E; Khera T; Welsch K; Tegtmeyer B; Hoehl S; Ciesek S; Brown RJP
    Viruses; 2019 Oct; 11(10):. PubMed ID: 31627415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.